PL3618811T3 - Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego - Google Patents

Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego

Info

Publication number
PL3618811T3
PL3618811T3 PL18723453T PL18723453T PL3618811T3 PL 3618811 T3 PL3618811 T3 PL 3618811T3 PL 18723453 T PL18723453 T PL 18723453T PL 18723453 T PL18723453 T PL 18723453T PL 3618811 T3 PL3618811 T3 PL 3618811T3
Authority
PL
Poland
Prior art keywords
sublingual
nasal
lung
silica particles
porous silica
Prior art date
Application number
PL18723453T
Other languages
English (en)
Inventor
Adam Feiler
Chunfang Zhou
Paulina PASZKIEWICZ
Xin XIA
Original Assignee
Nanologica Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanologica Ab filed Critical Nanologica Ab
Publication of PL3618811T3 publication Critical patent/PL3618811T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00—Silicon; Compounds thereof
    • C01B33/113—Silicon oxides; Hydrates thereof
    • C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
    • C01B33/124—Preparation of adsorbing porous silica not in gel form and not finely divided, i.e. silicon skeletons, by acidic treatment of siliceous materials
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/14—Pore volume
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/16—Pore diameter

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18723453T 2017-05-04 2018-05-03 Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego PL3618811T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1750544 2017-05-04
PCT/EP2018/061436 WO2018202818A1 (en) 2017-05-04 2018-05-03 A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery
EP18723453.9A EP3618811B1 (en) 2017-05-04 2018-05-03 A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery

Publications (1)

Publication Number Publication Date
PL3618811T3 true PL3618811T3 (pl) 2021-04-06

Family

ID=62143135

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18723453T PL3618811T3 (pl) 2017-05-04 2018-05-03 Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego

Country Status (11)

Country Link
US (1) US11285107B2 (pl)
EP (1) EP3618811B1 (pl)
JP (1) JP7048642B2 (pl)
KR (1) KR102579524B1 (pl)
CN (1) CN110603034A (pl)
AU (1) AU2018262708B2 (pl)
CA (1) CA3059099C (pl)
DK (1) DK3618811T3 (pl)
ES (1) ES2837675T3 (pl)
PL (1) PL3618811T3 (pl)
WO (1) WO2018202818A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3618811B1 (en) 2017-05-04 2020-09-30 Nanologica AB A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
US20220280602A1 (en) * 2019-07-31 2022-09-08 Lemonex Inc. Anticancer agent and method for preparation of porous silica particle
GB201916121D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916130D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916122D0 (en) 2019-11-06 2019-12-18 Nanologica Ab New compositions
GB201916117D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
WO2021211738A1 (en) * 2020-04-15 2021-10-21 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for antiviral treatment
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
GB2355711B (en) 1999-10-27 2003-12-24 Agilent Technologies Inc Porous silica microsphere scavengers
US6596262B2 (en) * 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6485707B2 (en) * 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
FI20060428L (fi) * 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
KR20100022499A (ko) 2007-06-04 2010-03-02 올테크 어소시에이츠, 인크. 실리카 입자 및 이의 제조방법 및 사용방법
GB0714134D0 (en) 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
MX2010002633A (es) * 2007-09-07 2010-05-20 Epigenesis Pharmaceuticals Llc Composiciones para inahalacion de dheas.
WO2009101110A2 (en) 2008-02-11 2009-08-20 Alfonso Garcia-Bennet Method for manufacturing mesoporous materials, materials so produced and use of mesoporous materials.
EP2251038B1 (en) * 2008-03-11 2017-05-10 ASKA Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
AU2011303849A1 (en) * 2010-09-14 2013-04-04 Nanologica Ab Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
PT3104853T (pt) 2014-02-10 2020-01-14 Respivant Sciences Gmbh Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
CN107072951A (zh) * 2014-07-22 2017-08-18 雷莫内克斯生物制药有限公司 用于递送生物活性物质或蛋白质的组合物及其用途
US20160090603A1 (en) * 2014-09-30 2016-03-31 Sandia Corporation Delivery platforms for the domestication of algae and plants
US20180169009A1 (en) * 2015-06-01 2018-06-21 Patrick Johnson Nanobiocomposite compositions and methods
JP7179245B2 (ja) * 2016-02-29 2022-11-29 アンプリコン アクチエボラグ ニコチンの蒸発及び吸入装置
EP3618811B1 (en) 2017-05-04 2020-09-30 Nanologica AB A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery

Also Published As

Publication number Publication date
WO2018202818A1 (en) 2018-11-08
AU2018262708B2 (en) 2021-06-03
EP3618811B1 (en) 2020-09-30
US20200069588A1 (en) 2020-03-05
CN110603034A (zh) 2019-12-20
KR20190142386A (ko) 2019-12-26
AU2018262708A1 (en) 2019-11-28
ES2837675T3 (es) 2021-07-01
JP7048642B2 (ja) 2022-04-05
US11285107B2 (en) 2022-03-29
JP2020518620A (ja) 2020-06-25
CA3059099C (en) 2023-06-27
EP3618811A1 (en) 2020-03-11
KR102579524B1 (ko) 2023-09-18
DK3618811T3 (da) 2020-12-21
CA3059099A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
PL3618811T3 (pl) Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego
ZA201900979B (en) Electronic cigarette with mass air flow sensor
HK1257973A1 (zh) 確定用於媒體傳輸的媒體傳遞事件位置
PL3298911T3 (pl) Papieros elektroniczny ze zintegrowaną dyszą do zasysania
PL3554295T3 (pl) Produkt dla osób palących, dla dostarczania na żądanie zwiększonej ilości kompozycji prekursora aerozolowego, wkład, oraz powiązany sposób
EP3292773A4 (en) ELECTRONIC CIGARETTE AND METHOD FOR MANUFACTURING THE LATTER ASSEMBLY THEREOF
IL292251A (en) Use of anti-static materials in air passages in the process of thermal condensation of an aerosol
WO2012110258A3 (de) Rauchfreie zigarette, zigarre oder pfeife
PT3864987T (pt) Inalador de aroma sem combustão e método de libertação de aerossol
AU201812272S (en) Nicotine Inhaler
PL3508078T3 (pl) Zestaw papierosowy do wdychania przez nos typu naciskowego z funkcją podgrzewania
PL3694349T3 (pl) Inhalator, w szczególności elektroniczny produkt papierosowy
DK3522962T3 (en) A nasal delivery system
PT3099641T (pt) Substrato dotado de um revestimento baseado em esmalte, material de esmalte, bem como método para revestimento de um substrato de vidro ou vitrocerâmica
CA188503S (en) Metered-dose inhaler mouthpiece
EP3081605A4 (en) EMISSIONSING COATING FILM, METHOD FOR THE MANUFACTURE THEREOF AND FUNCTIONAL CONSTRUCTION MATERIAL FOR WINDOWS AND DOORS THEREWITH
CA189046S (en) Mist inhaler
EP3337944A4 (en) Evacuation head with ceramic heater for vig unit manufacture
PL3310731T3 (pl) Wyrób powlekany sekwencyjnie aktywowaną powłoką niskoemisyjną i/lub sposób jego wytwarzania
PL3558037T3 (pl) Układ napełniania inhalatora aerozolu
HK1199142A1 (en) Mercury vapour discharge lamp and method for the manufacture thereof
EP3418256A4 (en) METHOD FOR MANUFACTURING POROUS SILICA PARTICLE OF C UR-BARK TYPE
IL229771B (en) Peptide preparations for the treatment of lung damage, asthma, anaphylaxis, angioedema, systemic syndromes of vascular permeability and nasal congestion
GB201717714D0 (en) Nasal endotracheal tube assembly
EP4034207C0 (en) DRY POWDER INHALATOR FOR PULMONARY OR NASAL ADMINISTRATION